Liquid biopsy of sclc chemosensitivity

Access through your institution Buy or subscribe Small-cell lung cancer (SCLC) is arguably the most-aggressive form of lung cancer. Most patients with SCLC present with metastatic disease

and have limited treatment options; although novel therapies are now on the horizon, platinum-based chemotherapy remains the current mainstay therapy. Frustratingly, most SCLCs are initially

chemosensitive, but later relapse; patients with chemorefractory disease have even more dismal outcomes, and are key candidates for experimental therapies. In a new study, a novel tool has

been developed that can inform on chemosensitivity prior to treatment. Information on the molecular landscape of SCLC is limited owing to challenges in obtaining high-qualify tumour samples,

which has in turn been a barrier to the identification of prognostic and predictive biomarkers, and thus to therapeutic advances. As Caroline Dive, who co-led the new study, explains, “no

molecular-based tests are available to facilitate patient management, and the chemosensitive versus chemorefractory designation is based on a rather arbitrary clinical observation of a

90-day timeframe for disease relapse after chemotherapy.” This situation led Dive and coworkers to probe circulating tumour cells (CTCs) from the blood for insights into the genomic

landscape of SCLC. “We had previously shown that SCLC CTCs are prevalent, and developed a methodology to isolate them and profile their DNA. This provided the potential to perform a simple

blood test to enable molecular analyses of tumour cells in order to increase our understanding of the disease.” This is a preview of subscription content, access via your institution ACCESS

OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on

SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about

institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * Carter, L. _ et al_. Molecular analysis of circulating tumor cells identifies distinct copy-number

profiles in patients with chemosensitive and chemorefractory small-cell lung cancer. _Nat. Med._ http://dx.doi.org/10.1038/nm.4239 (2016) Download references Authors * David Killock View

author publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Killock, D. Liquid biopsy

of SCLC chemosensitivity. _Nat Rev Clin Oncol_ 14, 2 (2017). https://doi.org/10.1038/nrclinonc.2016.201 Download citation * Published: 06 December 2016 * Issue Date: January 2017 * DOI:

https://doi.org/10.1038/nrclinonc.2016.201 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not

currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative